D.E. Shaw & Co’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

D.E. Shaw & Co’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,000	Closed	-$264K	–	6116
2021 Q4	$264K	Sell	10,000 -2,000	-17%	-$155K	﹤0.01%	4742
2021 Q3	$1.21M	Buy	+12,000	New	+$1.41M	﹤0.01%	3453
2020 Q3	–	Sell	-30,000	Closed	-$4.68M	–	4263
2020 Q2	$4.68M	Sell	30,000 -10,000	-25%	-$1.52M	0.01%	1697
2020 Q1	$5.77M	Buy	40,000 +30,000	+300%	+$5.79M	0.01%	1367
2019 Q4	$2.04M	Buy	+10,000	New	+$1.82M	﹤0.01%	2450

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

D.E. Shaw & Co's RETA Position: Q3 2023 in Review

D.E. Shaw & Co sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 6,075 shares — an estimated $619K sold.

D.E. Shaw & Co first reported a position in RETA in Q3 2018 and held it in 14 quarters. The position peaked at $12.2M in Q4 2022. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

D.E. Shaw & Co reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
D.E. Shaw & Co sold 6,075 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $619K.
D.E. Shaw & Co first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 14 quarters.
D.E. Shaw & Co's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $12.2M in Q4 2022.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on D.E. Shaw & Co's 13F filing for Q3 2023, filed 14 Nov 2023.